WATERTOWN, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development
of RNAi-based therapeutics, today announced its participation in a panel
discussion on RNAi therapeutics at the 16th Annual BIO CEO &
Investor Conference. Douglas M. Fambrough, PhD, the company's President
and CEO, is scheduled to take part in a Therapeutic Workshop entitled:
"Delivering the [RNAi] Goods" to be held on Monday, February 10th,
at 10:30 a.m. Eastern Standard Time.
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and
development of innovative treatments for rare inherited diseases
involving the liver and for cancers that are genetically defined.
Dicerna is using its proprietary RNA interference (RNAi) technology
platform to build a broad pipeline in these therapeutic areas and
intends to discover, develop and commercialize novel therapeutics either
on its own or in collaboration with pharmaceutical partners.
Dicerna Pharmaceuticals, Inc.
James E. Dentzer,
Chief Financial Officer
Chris Erdman, 781-235-3060
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media